At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 150 enrolled
Drug / intervention
GSK561679 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
In Brief
A Phase 2 clinical trial evaluating GSK561679 and Placebo for Depressive Disorder, Major. Completed, enrolled 150 participants across 18 sites.
Detailed Summary
This six-week study will evaluate the efficacy, safety and tolerability of GSK561679 compared to placebo in female subjects with major depressive disorder
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepressive Disorder, Major
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2008
Enrollment StartOct 2008
Primary CompletionJun 2010
TodayJul 2026
First PostedAug 13, 2008
Enrollment StartOct 2, 2008
Primary CompletionJun 18, 2010
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 17.9 years ago
Interventions
GSK561679drug
GSK561679
Placeboother
Placebo